

# Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry 2016

<https://marketpublishers.com/r/G0C64BB31FCEN.html>

Date: January 2016

Pages: 140

Price: US\$ 2,800.00 (Single User License)

ID: G0C64BB31FCEN

## Abstracts

The Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry 2016 is a professional and in-depth study on the current state of the Dental Implants industry.

The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Dental Implants market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Dental Implants industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.

With 161 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **1 INDUSTRY OVERVIEW**

1.1 Basic Information of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

1.1.1 Definition of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

1.1.2 Segments of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

1.1.3 Applications of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

1.1.4 Characteristics of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

1.2 Development Overview of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

1.3 Enter Barriers Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

### **2 COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS INTERNATIONAL AND CHINA MARKET ANALYSIS**

2.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry International Market Analysis

2.1.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications International Market Development History

2.1.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Competitive Landscape Analysis

2.1.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications International Main Regions Development Status

2.1.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications International Market Development Trend

2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry China Market Analysis

2.2.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications China Market Development History

2.2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications China Main Regions Development Status

2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications

International and China Market Comparison Analysis

### **3 ENVIRONMENT ANALYSIS OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS**

3.1 International Economy Analysis

3.2 China Economy Analysis

3.3 Policy Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

3.4 News Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

### **4 ANALYSIS OF REVENUE BY SEGMENTS**

4.1 Global Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments 2011-2016

4.2 Global Revenue Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments 2011-2016

4.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Segments

### **5 ANALYSIS OF REVENUE BY REGIONS AND APPLICATIONS**

5.1 Global Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions 2011-2016

5.2 2011-2016 North America Revenue and Revenue Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

5.3 2011-2016 Europe Revenue and Revenue Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

5.4 2011-2016 Japan Revenue and Revenue Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

5.5 2011-2016 China Revenue and Revenue Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

### **6 ANALYSIS OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS REVENUE MARKET STATUS 2011-2016**

6.1 Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016

6.2 Revenue Market Share Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016

6.3 Revenue Overview of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016

6.4 Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016

## **7 ANALYSIS OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS INDUSTRY KEY PLAYERS**

7.1 Roche

7.1.1 Company Profile

7.1.2 Revenue and Gross Margin

7.1.3 Roche SWOT Analysis

7.2Dako (Agilent Technologies)

7.2.1 Company Profile

7.2.2 Revenue and Gross Margin

7.2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis

7.3 Merck

7.3.1 Company Profile

7.3.2 Revenue and Gross Margin

7.3.3 Merck SWOT Analysis

7.4 BD

7.4.1 Company Profile

7.4.2 Product Picture and Specifications

7.1.3 Revenue and Gross Margin

7.4.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis

7.5 Abbott

7.5.1 Company Profile

7.5.2 Product Picture and Specifications

7.5.3 Revenue and Gross Margin

7.5.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis

7.6 Genesys Biolabs(20/20GeneSystems)

7.6.1 Company Profile

7.6.2 Revenue and Gross Margin

7.6.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT

## Analysis

### 7.7 Affymetrix

7.7.1 Company Profile

7.7.2 Product Picture and Specifications

7.7.3 Revenue and Gross Margin

7.7.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT

## Analysis

### 7.8 Agendia

7.8.1 Company Profile

7.8.2 Product Picture and Specifications

7.8.3 Revenue and Gross Margin

7.8.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT

## Analysis

### 7.9 ALMAC

7.9.1 Company Profile

7.9.2 Revenue and Gross Margin

7.9.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT

## Analysis

### 7.10 Arrayit

7.10.1 Company Profile

7.10.2 Revenue and Gross Margin

7.10.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT

## Analysis

### 7.11 Biocartic

7.11.1 Company Profile

7.11.2 Product Picture and Specifications

7.11.3 Revenue and Gross Margin

7.11.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT

## Analysis

### 7.12 BG Medicine

7.12.1 Company Profile

7.12.2 Product Picture and Specifications

7.12.3 Revenue and Gross Margin

7.12.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT

## Analysis

### 7.13 KEGG EXPRESSION Database

7.13.1 Company Profile

7.13.3 Revenue and Gross Margin

7.13.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT

Analysis

7.14 Thermo Fisher

7.14.1 Company Profile

7.14.2 Product Picture and Specifications

7.14.3 Revenue and Gross Margin

7.14.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT

Analysis

7.15 BGI

7.15.1 Company Profile

7.15.2 Revenue and Gross Margin

7.15.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT

Analysis

## **8 SALES PRICE AND GROSS MARGIN ANALYSIS**

8.1 Analysis of Cost, Gross and Gross margin

8.1.1 Cost Analysis

8.2 Gross Margin Analysis

## **9 MARKETING TRADER OR DISTRIBUTOR ANALYSIS OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS**

9.1 Marketing Channels Status of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

9.2 Business Model of Commercializing Biomarkers Service Supplier

## **10 DEVELOPMENT TREND OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS INDUSTRY 2016-2021**

10.1 Revenue Overview of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2016-2021

10.2 Gross Margin Overview of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2016-2021

## **11 INDUSTRY CHAIN SUPPLIERS OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS WITH CONTACT INFORMATION**

11.1 Equipment Suppliers of Commercializing Biomarkers in Therapeutic and

Diagnostic Applications with Contact Information

11.2 Major Suppliers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information

11.3 Key Consumers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications with Contact Information

11.4 Supply Chain Relationship Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

## **12 NEW PROJECT SWOT ANALYSIS OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS**

## **13 CONCLUSION OF THE GLOBAL COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS INDUSTRY 2016**

### **List of Tables and Figures**

Figure some techniques of biological markers for research 2

Table Segments of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2

Table, the characteristics of biomarkers and related industry 4

Table Global Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players 5

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Development History 8

Figure Global Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 9

Figure Global Major Player Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2015 10

Figure Global Main Regions Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2015 11

Figure Pre-competitive collaboration can help expand published shared knowledge 11

Figure China Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2015 12

Table China Main Regions Development Status 13

Figure Global & China Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 13

Figure Global GDP Map 2014 14

Figure USA GDP Change 2005-2014 15

Figure USA CPI Change 2011-2015 15

Figure EU GDP Change 2005-2014 16

Figure German CPI Change 2011-2015 16

Figure UK CPI Change 2011-2015 17

Figure Japan GDP Change 2005-2014 17

Figure Japan CPI Change 2005-2014 18

Figure China GDP Change 2005-2014 18

Figure China CPI Change 2005-2014 19

Figure China PPI Growth Rate 2005-2014 19

Table Policy of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 20

Table Industry News 1 of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 20

Table Global Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments 2011-2016 (M USD) 22

Table Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments 2011-2016 22

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2011 23

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2012 23

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2013 24

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2014 24

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2015 25

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Segments in 2016 25

Figure Global Revenue Growth Rate of Consumables 2011-2016 26

Figure Global Revenue Growth Rate of Services 2011-2016 26

Figure Global Revenue Growth Rate of Software 2011-2016 27

Table North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Segments 27

Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Segments 27

Table Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Segments 27

Table China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Segments 28



Table Global Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions 2011-2016 (M USD) 29

Table Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions 2011-2016 29

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2011 30

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2012 30

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2013 31

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2014 31

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2015 32

Figure Global Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions in 2016 32

Table North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Applications 33

Figure North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Revenue Growth Rate 33

Table Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Applications 34

Figure Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Revenue Growth Rate 34

Table Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Applications 35

Figure Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Revenue Growth Rate 35

Table China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Applications 36

Figure China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Revenue Growth Rate 36

Table Global and China Major Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue of 2011-2016 (M USD) 37

Table Global and China Major Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share of 2011-2016 37

Table China Major Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue of 2011-2016 (M USD) 38

Table China Major Players Commercializing Biomarkers in Therapeutic and Diagnostic

Applications Revenue Market Share of 2011-2016 38

Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2011 39

Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2012 40

Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2013 41

Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2014 42

Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2015 43

Figure Global Revenue Market Share of Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2016 44

Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2011 44

Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2012 45

Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2013 45

Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2014 46

Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2015 46

Figure China Revenue Market Share Major Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in 2016 47

Figure Global Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 47

Figure China Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 48

Figure 2011-2016 Global and China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Comparison 48

Table Cost of Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Players 2011-2016 (M USD) 48

Table Gross of Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Players 2011-2016 (M USD) 49

Table Gross Margin of Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Players 2011-2016 50

Figure Gross Margin of Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Players in 2014 51

Table Roche Company Profile List 52

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Roche 2011-2016 53

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Roche 2011-2016 53

Table Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 53

Table Dako (Agilent Technologies) Information List 54

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 55

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 55

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 56

Table Merck Company Profile List 56

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Merck 2011-2016 57

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Merck 2011-2016 58

Table Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 58

Table BD Information List 59

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of BD 60

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 60

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 61

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 61

Table Abbott Information List 62

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture 63

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 63

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 64

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 64

Table Genesys Biolabs(20/20GeneSystems) Information List 65

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 66

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 66

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 67

Table Affymetrix Information List 67

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of Affymetrix 68

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 69

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 70

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 70

Table Agendia Information List 71

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of Agendia 72

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 73

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications  
Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and  
Diagnostic Applications 2011-2016 73

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications  
Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT  
Analysis 74

Table ALMAC Information List 74

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications  
Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of  
Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 75

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications  
Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and  
Diagnostic Applications 2011-2016 76

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications  
Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT  
Analysis 76

Table Arrayit Information List 77

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications  
Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of  
Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 78

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications  
Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and  
Diagnostic Applications 2011-2016 78

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications  
Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT  
Analysis 79

Table Biocartic Information List 79

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture  
and Specifications of Biocartic 80

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications  
Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of  
Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 81

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications  
Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and  
Diagnostic Applications 2011-2016 81

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications  
Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT  
Analysis 82

Table BG Medicine Information List 82

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of BG Medicine 83

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 83

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 84

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 84

Table KEGG EXPRESSION Database Information List 85

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 86

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 86

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 87

Table Thermo Fisher Information List 87

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture and Specifications of Thermo Fisher 88

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 88

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 89

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT Analysis 89

Table BGI Information List 90

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, Cost, Gross (M USD) Revenue Growth Rate and Gross Margin of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2011-2016 91

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic and

Diagnostic Applications 2011-2016 92

Table Commercializing Biomarkers in Therapeutic and Diagnostic Applications  
Commercializing Biomarkers in Therapeutic and Diagnostic Applications SWOT  
Analysis 92

Table Cost Analysis 94

Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications  
Manufacturer Profit Model 94

Figure Marketing Channels Status of Commercializing Biomarkers in Therapeutic and  
Diagnostic Applications 96

Figure Business Model of Commercializing Biomarkers Service Supplier 97

Figure Global Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic  
and Diagnostic Applications 2016-2021 98

Figure China Revenue and Growth Rate of Commercializing Biomarkers in Therapeutic  
and Diagnostic Applications 2016-2021 99

Figure Global and China Commercializing Biomarkers in Therapeutic and Diagnostic  
Applications Revenue Comparison 2016-2021 99

Figure Gross Margin 2016-2021 100

Table Equipment Suppliers of Commercializing Biomarkers in Therapeutic and  
Diagnostic Applications with Contact Information 101

Table Major Suppliers of Commercializing Biomarkers in Therapeutic and Diagnostic  
Applications with Contact Information 101

Table Key Consumers of Commercializing Biomarkers in Therapeutic and Diagnostic  
Applications with Contact Information 102

Figure Biomarkers connect bench to bedside and create a continuous feedback loop for  
innovation. 103

Figure Data standards and semantics enable continuous information flow across  
industries. 104

Table New Project SWOT Analysis of Commercializing Biomarkers in Therapeutic and  
Diagnostic Applications 105

Table Pharmacogenomic Biomarkers in Drug Labeling 111

## I would like to order

Product name: Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry 2016

Product link: <https://marketpublishers.com/r/G0C64BB31FCEN.html>

Price: US\$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0C64BB31FCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



